Randomized, Crossover Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease Characterized by Low Tear Volume

The purpose of this Phase 2a study is to assess changes in tear volume by the non-invasive techniques Ultra High Resolution Optical Coherence Tomography (UHR-OCT) following the administration of P-321 Ophthalmic Solution or Placebo in subjects with tear deficient dry eye disease.

开始日期2016-07-01

申办/合作机构

Parion Sciences, Inc.

NCT02831387 / Terminated临床2期

Randomized, Double-Masked, Parallel Group Study of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease Assessing Safety and Efficacy Over 28 Days

The purpose of this study is to evaluate the effect of treatment with 0.017% P-321 on Dry Eye Symptoms.

开始日期2016-07-01

申办/合作机构

Parion Sciences, Inc.

NCT02242032 / Completed临床1期

A Double-Masked, Randomized, Placebo-Controlled Dose Escalation Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease

The purpose of this study is to assess the safety and tolerability of P-321 Ophthalmic Solution in subjects with mild to moderate dry eye disease.

开始日期2014-07-01

申办/合作机构

Parion Sciences, Inc.

100 项与 Voluloride 相关的临床结果

登录后查看更多信息

100 项与 Voluloride 相关的转化医学

登录后查看更多信息

100 项与 Voluloride 相关的专利（医药）

登录后查看更多信息

项与 Voluloride 相关的文献（医药）

2012-09-01·Scandinavian Journal of Immunology4区 · 医学

A Novel Cytotoxic T lymphocyte Epitope Analogue with Enhanced Activity Derived From Cyclooxygenase‐2

4区 · 医学

Article

作者: Y. M. Qi ; M. X. Zhai ; Y. J. He ; M. Sun ; Y. H. Wu ; X. Chen ; R. R. Shi ; W. J. Zhai ; Y. F. Gao ; Z. Y. Wu

AbstractCyclooxygenase‐2 is a promising target for cancer immunotherapy. Here, we designed the analogues p321‐9L and p321‐1Y9L (YLIGETIKL) from cyclooxygenase‐2‐derived native peptide p321. Then, we tested the binding affinity and stability of the analogues and their ability to elicit specific immune response both in vitro (from PBMCs of HLA‐A*02+ healthy donors) and in vivo (from HLA‐A2.1/Kb transgenic mice). Our results indicated that the activity of cytotoxic T lymphocytes induced by p321‐9L and p321‐1Y9L was more potent than that of p321. In conclusion, the epitope analogue, especially p321‐1Y9L, may be a good candidate which could be used to the immunotherapy of patients with tumours expressing cyclooxygenase‐2.

100 项与 Voluloride 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
干眼症	临床2期	-	Parion Sciences, Inc.	-
干眼症	临床2期	-	Shire Pharmaceuticals Services Ltd.	-
干眼综合征	药物发现	美国	Parion Sciences, Inc.	2016-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02831387 (CTgov)	临床2期	干眼综合征	47	P-321 Ophthalmic Solution	襯醖製鹽鏇鏇襯觸願襯(鬱齋鬱遞淵糧齋淵選膚) = 顧膚觸繭鹹憲鹹膚獵築鹹網廠簾廠淵襯鹹艱膚 (餘構鑰鹽齋積構壓鏇糧, 網獵範鏇觸選範鬱蓋製 ~ 簾網鹽觸獵積築鬱鑰簾) 更多	-	2018-10-11
NCT02824913 (CTgov)	临床2期	干眼综合征	1	P-321 Ophthalmic Solution (P-321 Ophthalmic Solution)	膚願醖鑰憲鏇壓窪齋選(選顧願窪顧淵鬱顧齋構) = 淵蓋網夢築選鑰壓鬱夢積範醖鹹遞鹹觸廠廠憲 (鹽艱製鑰壓蓋網網鹽鹹, 餘餘鹹選選範鹹壓衊餘 ~ 醖蓋觸鬱獵獵遞獵齋憲) 更多	-	2018-01-19
NCT02824913 (CTgov)	临床2期	干眼综合征	1	P-321 Ophthalmic Solution placebo (Drug: P-321 Ophthalmic Solution Placebo)	膚願醖鑰憲鏇壓窪齋選(選顧願窪顧淵鬱顧齋構) = 齋範願廠積鬱窪築顧艱積範醖鹹遞鹹觸廠廠憲 (鹽艱製鑰壓蓋網網鹽鹹, 築蓋襯壓製構衊鏇壓醖 ~ 鑰蓋鑰願齋餘窪鹽衊構) 更多	-	2018-01-19
ARVO2014	N/A	-	-	P-321 0.1%	(襯廠製醖糧積憲鹹繭願) = increased slightly during multiple dose administration reaching steady state levels by Day 4 獵願簾鹹鹽簾選構範膚 (膚廠鑰鬱夢鏇製鏇夢襯 ) 更多	-	2014-04-01